Genetic polymorphism of UDP-glucuronosyltransferase [UGT2B15] and glucuronidation of paracetamol in healthy population

Inter individual variability in polymorphic UDP-glucuronosyltransferase [UGT2B15] has been associated with varied glucuronidation level. The present project was designed to determine the genetic polymorphism of UDP-glucuronosyltransferase [UGT2B15] and glucuronidation of paracetamol in healthy [male=59 and female=50] population. The association between genotype [UGT2B15] and phenotype [paracetamol glucuronidation] has been evaluated. According to trimodal model, genotypes and phenotypes were categorized as fast, intermediate and slow glucuronidators. Presence of wild type allele illustrated a UGT2B15 genotype as fast glucuronidator. The glucuronidation status was investigated by HPLC analysis of paracetamol. Ratio of paracetamol glucuronide to paracetamol was determined with two antimodes at glucuronidation ratio of 0.3 and 1.8. In our study, 7% and 12% of population was distributed as slow glucuronidators by phenotype and genotype, respectively and association between phenotype and genotype was good for analysis of glucuronidation status as displayed by kappa value [0.792]

Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study

Deferiprone [1, 2 dimethyl-3-hydroxypyrid-4-one] is considered to be the standard iron chelator. Pharmacokinetic studies of generic formulations are required in local condition before placed on the market. High performance liquid chromatographic [HPLC] method was used for quantification of deferiprone in human plasma using UV/VIS detector. Chromatographic separation was carried out on C[18] column, with a mobile phase of methanol-buffer [18:82, v/v], pH 3.5, and caffeine was used as an internal standard. The calibration curve was linear over the range 0.25-10 micro g/mL in human plasma [R[2] = 0.9994]. After oral administration of deferiprone [500 mg] to human, the plasma concentration-time curve of deferiprone was conformed to two-compartment open model. The deferiprone plasma concentration showed a rapid absorption and average area under the plasma concentration-time curve [AUC] of deferiprone was 17.0 +/- 1.23 h. micro g/mL. Average absorption and elimination half-life values of deferiprone of 24 volunteers were 0.62 +/- 0.12 and 2.65 +/- 0.43 hours. This study confirms the rapid absorption of deferiprone in humans. AUC was similar to that previously reported but C[max] was slightly lower than that stated in the literature

Body image dissatisfaction as an indicator of low self-esteem and disturbed eating attitude in adults

The present research was conducted in order to assess the relationship of body image dissatisfaction with low self-esteem and disturbed eating attitude in adults. After detailed literature review certain hypotheses were formulated: [1] There would be a negative relationship between body image dissatisfaction and self-esteem in adults. [2] There would be a positive relationship between body image dissatisfaction and disturbed eating attitude in adults. The sample of the research consisted of 50 males and 50 females with an age range of 20-25 years, belonging to middle class socioeconomic status and with the qualification of at least graduation. Body image dissatisfaction was measured by the Body-Esteem Scale-Revised [BES; Mendelson, White, and Mendelson, 1998]; Self-esteem was measured by using the Rosenberg Self-Esteem Scale [RSES; Rosenberg, 1965], while Eating attitude was measured using the Eating Attitude Test [EAT; Garner and Garfinkel, 1979]. Data analysis was done using Pears on Product Moment Coefficient of Correlation. The results were consistent with the first hypothesis as body image dissatisfaction was negatively correlated with self-esteem [r=-.293, p<.05]. The results were inconsistent with the second hypothesis as insignificant correlation was found between body image dissatisfaction and eating attitude. 106, p>. 05]